AGT and hypertensive disorder: By treating SHR with pressor and sub-pressor doses of AT1 receptor antagonist, Kumai et al. (2008) showed that both attenuated the superoxide levels in BA and MCA, reversed hypertension-induced hypertrophy and oxidative stress, and improved cerebral blood flow autoregulation, suggesting the blockade of Ang II (and its downstream pathways) as the underlying mechanism.